Chiasma, Inc. (CHMA) Misses Q4 EPS by 8c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/2/2026

1. RELIANCE:I
2. LYB
3. BP
4. REGN
5. LITE
6. CL
7. OKTA
8. NWG
9. NWG:LN
10. PERI

Go back to Chiasma, Inc. (CHMA) Misses Q4 EPS by 8c

Chiasma (CHMA) Has Enough Cash To Reach Profitability - Oppenheimer

March 15, 2016 7:48 AM EDT

Chiasma (NASDAQ: CHMA) reported 4Q15/FY2015, ending the quarter with $148.8M in cash, which Oppenheimer analyst, Christopher Marai, believes is sufficient to fund operations through profitability, assuming US approval. The company also announced total aggregate R&D and SG&A including stock-based comp of $80-88M. No change to Outperform rating or $43 PT.

The Phase-3 "MPOWERED" trial for an EU regulatory submission initiated. EU submission expected 2019. The trial will evaluate the non-inferiority (20% margin) of octreotide capsules to injectable... More